VivoSeq
Other

Medication Adherence

0

Pipeline Programs↗

5

Active Trials↗

2

Companies Involved↗

Medication Adherence is an early-stage landscape with 0 programs across 2 companies. The most active players are Boehringer Ingelheim, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed8 · 53%
Withdrawn2 · 13%
Active, not recruiting2 · 13%
Recruiting1 · 7%
Enrolling by invitation1 · 7%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
Recruiting·—·Phase 2/3·NCT06958627·964 enrolled
Pharmacist-CHW Team to Improve Medication Adherence and Reduce Hypertension
Active, not recruiting·UUniversity of Arizona·Preclinical·NCT05470439·217 enrolled
Monitoring Medication Adherence in Patients Aged ≥65 Years on Polypharmacy: A Randomized Clinical Trial of the Itaca Mobile App vs. Usual Care
Active, not recruiting·UUniversity of Roma La Sapienza·Preclinical·NCT07631676·120 enrolled
A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer
Not yet recruiting·CChildren's Hospital Medical Center, Cincinnati·Preclinical·NCT07223463·160 enrolled
Addressing Psychosocial Comorbidities in HIV Treatment and Prevention: Phase 2b
Enrolling by invitation·UUniversity of Miami·Preclinical·NCT05352061·75 enrolled
Nicotine Replacement Therapy (NRT) Sampling and Selection to Increase Medication Adherence
Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT03276780·80 enrolled
Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence
Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT03538808·80 enrolled
Medication Adherence Monitoring Trial Using Smart Clinical Trial Application and Smart Watch
Completed·SSeoul National University Hospital·N/A·NCT05452512·16 enrolled
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
Completed·Pfizer logoPfizer·N/A·NCT04375150·355 enrolled
Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT01097421·329 enrolled
Next Generation Ingestible Sensors for Medication Adherence Measurement
Completed·—·Phase 3·NCT05592613·15 enrolled
Medication Adherence Therapy for Opioid Abusing Pain Patients
Completed·National Institute on Drug Abuse (NIDA)·Phase 1/2·NCT00249587·36 enrolled
Addressing Antihypertensive Medication Adherence Through EHR-enabled Teamlets in Primary Care
Completed·NNYU Langone Health·Preclinical·NCT05349422·1,842 enrolled
Mobile Health Interventions for Medication Adherence Among PLWH
Withdrawn·—·Phase 4·NCT04191278
Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice
Withdrawn·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT03205137

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)